Replies to post #108113 on Biotech Values

[mcbio]

Re: MNTA/generic Copaxone competition

Quote:
--------------------------------------------------------------------------------
I assume MNTA need only succeed on one of these four arguments. Is that correct?
--------------------------------------------------------------------------------

Yes.
Quote:
--------------------------------------------------------------------------------
…which of the four arguments do you see as holding the best chance for MNTA to succeed?
--------------------------------------------------------------------------------

Obviousness/double patenting, i.e. that the Orange Book patents are obvious extensions of older Copaxone patents.

Thanks Dew. And I apologize in advance if already discussed on the Board, but I don't recall a lot of chatter about the potential competition for MNTA as it relates to generic Copaxone. I assume MYL is potential competition, given their involvement in the Copaxone patent litigation. Who are the other main potential competitors that we know of or expect? And who is the biggest threat? Obviously, TEVA will likely not be competition here, since they have the branded drug in this instance.

[mcbio]

Re: MNTA/Copaxone "obviousness" argument

Quote:
--------------------------------------------------------------------------------
…which of the four arguments do you see as holding the best chance for MNTA to succeed?
--------------------------------------------------------------------------------

Obviousness/double patenting, i.e. that the Orange Book patents are obvious extensions of older Copaxone patents.

I would assume you are fairly confident that MNTA will in fact succeed on this argument. Is the general consensus in the analyst community and elsewhere that MNTA will not? One would think so given MNTA's market cap, although perhaps too many people are just too focused on the nearer-term potential issue of TEVA receiving approval for its generic Lovenox to see the opportunity that lies beyond for MNTA with generic Copaxone (and of course everything else in the pipeline from M118, FOBs, etc.). I.e., if we can be reasonably confident that MNTA will succeed on the "obviousness" argument in the Copaxone patent litigation, I'm really not all that worried at all even if TEVA does receive approval for its generic Lovenox in the near-term. In fact, I'm inclined to view such an event, and any material drop in MNTA's stock, as a potential buying opportunity.